RxDoctor Payments Data

Ashley Hilsabeck

Family · Pascagoula, MSNPI 1134495443

Payments from drug & device makers

$7,871in general payments, 2019–2025

Across 471 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Novo Nordisk$969
  • AbbVie$867
  • Boehringer Ingelheim$772
  • Bayer$619
  • AstraZeneca$565
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$7,871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,871 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$31,773
Medicare patients
172
Services billed
504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide114$118,166
JardianceEmpagliflozin67$86,049
OzempicSemaglutide63$63,907
MounjaroTirzepatide19$28,805
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,486
FarxigaDapagliflozin Propanediol12$17,947
Tresiba Flextouch U-100Insulin Degludec12$5,827
Atorvastatin Calcium401$2,900
Albuterol Sulfate HfaAlbuterol Sulfate111$2,807
Losartan Potassium325$2,488
Levothyroxine Sodium187$1,876
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,580
Gabapentin146$1,525
Omeprazole156$1,451
Pravastatin Sodium113$1,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,010$146,971133 claims
Boehringer IngelheimJardiance$772$86,04967 claims
Novo NordiskOzempic$969$63,90763 claims
GSKTrelegy Ellipta$465$18,48625 claims
AstraZenecaFarxiga$565$17,94712 claims
AbbVieSynthroid$867$1,11415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Pascagoula

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →